Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

An error was published in Table 2, row 5 of our manuscript in the July issue 2022 of Haematologica.¹ The number for the Pacritinib group was erroneously published as 17.9 (5/28) and should be 25.0 (19/76). The corrected Table 2 is shown here.

Corrected Table 2.

Spleen volume response and modified Total Symptom Score response rates among patients randomized to pacritinib versus best available therapy by subgroup: prior exposure to a JAK2 inhibitor (including ruxolitinib) and myelofibrosis subtype (primary vs. secondary after a prior diagnosis of polycythemia vera or essential thrombocythemia).